Dacomitinib (Vizimpro®) is indicated as monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/04/2019|
|Rapid review completed||13/05/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dacomitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies|
The HSE has approved reimbursement following confidential price negotiations (November 2019).